Atrial Fibrillation Market cover

Atrial Fibrillation Market by Procedures (Pharmacological Drugs, Catheter Ablation, Electric Cardioversion Anti-arrhythmic, Microwave, Cryoablation, Anti-coagulant, HIFU, Non-Pharmacological Treatments, Radiofrequency, Laser, and Maze Surgery), End-users (Ambulatory Surgical Centers, Hospitals, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: CG-2546
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 2
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global atrial fibrillation market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing cases of obesity, rapidly changing lifestyle, and rising incidence of hypertension.

Atrial Fibrillation Market summary

Atrial fibrillation or AFib is a kind of heart disorder that produces irregular heartbeats known as arrhythmia and can lead to blood clots, heart failure, strokes and other heart-related issues. Moreover, AFib is one of the most common chronic arrhythmia among people above the age of 65. According to the Centers for Disease Control and Prevention (CDC) estimation, approximately 12.1 million Americans are estimated to develop AFib by 2030 and the number is likely to increase owing to the rising number of the old population globally.

Patients with cardiovascular disease are at significant risk of multiple organ failures, such as rhythm and myocarditis disturbance and susceptible to the COVID-19. As per the data published by the government authorities of Wuhan, China, arrhythmia and acute cardiac damage are among the most common heart problems in patients with COVID-19 infection. Furthermore, a case report published in the Journal of the American Medical Association (JAMA) in February 2020 highlighted common problems among hospitalized patients including acute respiratory distress syndrome, arrhythmia, shock, acute cardiac damage, and acute respiratory distress syndrome.

Meanwhile, the intensive care unit (ICU) patients were more likely to experience the virus infection than non-ICU patient. In the year 2020 an article, 'Home Monitoring of Cardiac Devices in the Era of COVID-19,' summarized that digital platforms and innovative technology should be developed to support remote care, and more research on the role of tele-health. Several studies suggest that advanced automotive features, constant data collection, and distant patient monitoring are needed to guide best practices. Thus, it is expected to propel the market expansion during the forecast period.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing cardiovascular diseases, increasing geriatric population, and rising cases of stress-related ailments are some of the key factors propelling the market growth.
  • Increasing technological advancement and rising R&D activities on new products to treat ailment are expected to boost the market expansion during the forecast period.
  • Increasing preferences towards catheter ablation for cardiac arrhythmia treatment and growing medical tourism are fueling the market growth.
  • High complications rate and unfavorable preferences towards drugs over atrial fibrillation devices are anticipated to hinder the market expansion in the near future.
  • High cost involved in product manufacturing along with the lack of skilled healthcare technician handling devices are some of the restraining factors hampering the market growth in the coming years.
  • Ongoing development operational expertise by key pharmaceutical players to enhance the laboratory testing and favorable government policies are likely to offer immense opportunities for the market development in the long run.

Scope of the Report

The report on the global atrial fibrillation market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Atrial Fibrillation Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Procedures (Pharmacological Drugs, Catheter Ablation, Electric Cardioversion Anti-arrhythmic, Microwave, Cryoablation, Anti-coagulant, HIFU, Non-pharmacological Treatments, Radiofrequency, Laser, and Maze Surgery) and End-users (Ambulatory Surgical Centers, Hospitals, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Biosense Webster Inc.; Boehringer Ingelheim GmbH; AtriCure Inc.; Sanofi-Aventis; CardioFocus Inc.; Bristol-Myers Squibb Corp.; Boston Scientific Corp.; Endoscopic Technologies Inc.; Johnson & Johnson Ltd.; and St. Jude Medical Inc.

Market Segment Insights

Non-pharmacological treatment segment is expected to grow at a rapid pace

Based on procedures, the global atrial fibrillation market is segregated as pharmacological drugs, catheter ablation, electric cardioversion anti-arrhythmic, microwave, cryoablation, anti-coagulant, HIFU, non-pharmacological treatments, radiofrequency, laser, and maze surgery. The non-pharmacological treatment segment is expected to grow at a rapid pace during the forecast period owing to the common use of surgical devices for the treatment of cardiac arrhythmias. However, drugs for the treatment of atrial fibrillation are not always effective, thus, non-pharmacological treatments are extensively used. Such widespread adoption of non-pharmacological approaches is expected to fuel the segment growth in the coming years.

Atrial Fibrillation Market procedure

Ambulatory surgical centers segment is projected to expand at a considerable CAGR

On the basis of end-users, the market is segmented into ambulatory surgical centers, hospitals, and others. The ambulatory surgical centers segment is projected to expand at a considerable CAGR during the forecast period attributed to the well- established healthcare facilities, affordable treatment procedures, and availability of skilled labor. However, patients are opting for minimally invasive operations due to several benefits such as faster recovery time, lower surgical discomfort, hospital stay, and higher accuracy. These factors are estimated to upsurge the segment growth in the coming years.

North America is anticipated to constitute a key market share

In terms of regions, the global atrial fibrillation market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period owing to the growing number of patients related to atrial fibrillation and the presence of well-established key players in the region. According to the Center for Disease Control and Prevention (CDC) reports, around 2.7 to 6.1 million persons in the US had atrial fibrillation in 2017. Furthermore, as per the American Heart Association (AHA) reports in 2018, elevated blood pressure is one of the most common reasons of atrial fibrillation accounting for 14-22% of all atrial fibrillation cases in the US. Thus, it is estimated to boost the market in the region during the projected period.

Atrial Fibrillation Market region

Segments

Segments Covered in the Report

The global atrial fibrillation market has been segmented on the basis of

Procedures

  • Pharmacological Drugs
  • Catheter Ablation
  • Electric Cardioversion Anti-arrhythmic
  • Microwave
  • Cryoablation
  • Anti-coagulant
  • HIFU
  • Non-pharmacological Treatments
  • Radiofrequency
  • Laser
  • Maze Surgery

End-users

  • Ambulatory Surgical Centers
  • Hospitals
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • AtriCure Inc.
  • Sanofi-Aventis
  • CardioFocus Inc.
  • Bristol-Myers Squibb Corp.
  • Boston Scientific Corp.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • St. Jude Medical Inc.

Competitive Landscape

Some of the key players competing in the market are Biosense Webster Inc.; Boehringer Ingelheim GmbH; AtriCure Inc.; Sanofi-Aventis; CardioFocus Inc.; Bristol-Myers Squibb Corp.; Boston Scientific Corp.; Endoscopic Technologies Inc.; Johnson & Johnson Ltd.; and St. Jude Medical Inc. Most of these big players have implemented various marketing strategies such as partnerships, mergers & acquisitions, collaboration, and extensive service portfolio along with expanding service capacity on various geographies to secure competitive edge in their market position.

Atrial Fibrillation Market keyplayers

In May 2020, CardioFocus Inc. has declared that the advanced HeartLight X3 Endoscopic Ablation System (EAS) has been authorized by the US Food and Drug Administration (FDA) to cure drug-refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This device was designed to provide experts with a new degree of speed, control, and predictability, making it an ideal tool for AFib ablation. Tempus has announced in March 2021 that the US FDA has granted their ECG analysis platform breakthrough device designation. The tool, which was created in conjunction with Geisinger, aimed to help clinicians identify individuals who are at risk of developing atrial fibrillation.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Atrial Fibrillation Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Atrial Fibrillation Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Atrial Fibrillation Market - Supply Chain
  4.5. Global Atrial Fibrillation Market Forecast
     4.5.1. Atrial Fibrillation Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Atrial Fibrillation Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Atrial Fibrillation Market Absolute $ Opportunity
5. Global Atrial Fibrillation Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Atrial Fibrillation Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Atrial Fibrillation Demand Share Forecast, 2019-2026
6. North America Atrial Fibrillation Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Atrial Fibrillation Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Atrial Fibrillation Demand Share Forecast, 2019-2026
7. Latin America Atrial Fibrillation Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Atrial Fibrillation Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Atrial Fibrillation Demand Share Forecast, 2019-2026
8. Europe Atrial Fibrillation Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Atrial Fibrillation Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Atrial Fibrillation Demand Share Forecast, 2019-2026
9. Asia Pacific Atrial Fibrillation Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Atrial Fibrillation Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Atrial Fibrillation Demand Share Forecast, 2019-2026
10. Middle East & Africa Atrial Fibrillation Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Atrial Fibrillation Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Atrial Fibrillation Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Atrial Fibrillation Market: Market Share Analysis
  11.2. Atrial Fibrillation Distributors and Customers
  11.3. Atrial Fibrillation Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Biosense Webster Inc.
     11.4.2. Boehringer Ingelheim GmbH
     11.4.3. AtriCure Inc.
     11.4.4. Sanofi-Aventis
     11.4.5. CardioFocus Inc.
     11.4.6. Bristol-Myers Squibb Corp.
     11.4.7. Boston Scientific Corp.

Segments Covered in the Report

The global atrial fibrillation market has been segmented on the basis of

Procedures

  • Pharmacological Drugs
  • Catheter Ablation
  • Electric Cardioversion Anti-arrhythmic
  • Microwave
  • Cryoablation
  • Anti-coagulant
  • HIFU
  • Non-pharmacological Treatments
  • Radiofrequency
  • Laser
  • Maze Surgery

End-users

  • Ambulatory Surgical Centers
  • Hospitals
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Biosense Webster Inc.
  • Boehringer Ingelheim GmbH
  • AtriCure Inc.
  • Sanofi-Aventis
  • CardioFocus Inc.
  • Bristol-Myers Squibb Corp.
  • Boston Scientific Corp.
  • Endoscopic Technologies Inc.
  • Johnson & Johnson Ltd.
  • St. Jude Medical Inc.

Some of the key players competing in the market are Biosense Webster Inc.; Boehringer Ingelheim GmbH; AtriCure Inc.; Sanofi-Aventis; CardioFocus Inc.; Bristol-Myers Squibb Corp.; Boston Scientific Corp.; Endoscopic Technologies Inc.; Johnson & Johnson Ltd.; and St. Jude Medical Inc. Most of these big players have implemented various marketing strategies such as partnerships, mergers & acquisitions, collaboration, and extensive service portfolio along with expanding service capacity on various geographies to secure competitive edge in their market position.

Atrial Fibrillation Market keyplayers

In May 2020, CardioFocus Inc. has declared that the advanced HeartLight X3 Endoscopic Ablation System (EAS) has been authorized by the US Food and Drug Administration (FDA) to cure drug-refractory recurrent symptomatic paroxysmal atrial fibrillation (PAF). This device was designed to provide experts with a new degree of speed, control, and predictability, making it an ideal tool for AFib ablation. Tempus has announced in March 2021 that the US FDA has granted their ECG analysis platform breakthrough device designation. The tool, which was created in conjunction with Geisinger, aimed to help clinicians identify individuals who are at risk of developing atrial fibrillation.

Buy Report